Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Recommendation of "Hold" from Brokerages

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) has received an average recommendation of "Hold" from the twenty-five ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating and twelve have issued a buy rating on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $60.88.

Several research analysts have commented on the stock. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Sarepta Therapeutics from $50.00 to $25.00 and set a "hold" rating for the company in a research note on Tuesday, June 17th. Wolfe Research assumed coverage on shares of Sarepta Therapeutics in a research note on Tuesday, June 17th. They set a "peer perform" rating for the company. UBS Group dropped their price objective on shares of Sarepta Therapeutics from $188.00 to $85.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. BMO Capital Markets lowered shares of Sarepta Therapeutics from an "outperform" rating to a "market perform" rating and dropped their price objective for the stock from $120.00 to $70.00 in a research note on Monday, June 16th. Finally, Barclays lowered their target price on shares of Sarepta Therapeutics from $89.00 to $29.00 and set an "overweight" rating for the company in a research note on Tuesday, June 17th.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Byrne Asset Management LLC acquired a new position in Sarepta Therapeutics in the 1st quarter worth approximately $30,000. Center for Financial Planning Inc. acquired a new position in Sarepta Therapeutics in the 1st quarter worth approximately $31,000. Ancora Advisors LLC increased its holdings in Sarepta Therapeutics by 150.0% in the 1st quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company's stock worth $32,000 after buying an additional 300 shares during the period. Steward Partners Investment Advisory LLC boosted its position in Sarepta Therapeutics by 164.4% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock worth $38,000 after purchasing an additional 194 shares in the last quarter. Finally, Banque Transatlantique SA purchased a new stake in Sarepta Therapeutics in the 1st quarter worth approximately $44,000. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Sarepta Therapeutics Trading Up 0.6%

Sarepta Therapeutics stock opened at $18.98 on Wednesday. The stock has a market cap of $1.87 billion, a P/E ratio of -7.06 and a beta of 0.61. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.02 and a quick ratio of 2.46. Sarepta Therapeutics has a 1 year low of $18.30 and a 1 year high of $164.52. The firm's 50 day moving average price is $41.67 and its 200-day moving average price is $81.09.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. The company had revenue of $744.86 million for the quarter, compared to the consensus estimate of $685.75 million. During the same quarter in the previous year, the business earned $0.73 EPS. The company's quarterly revenue was up 80.2% on a year-over-year basis. On average, equities analysts predict that Sarepta Therapeutics will post 2.67 earnings per share for the current fiscal year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.